Abstract P3-01-05: Influence of hormone replacement therapy following bilateral salpingo-oophorectomy on mammographic breast density in women newly diagnosed with breast cancer

Background: Studies have demonstrated that use of hormone replacement therapy (HRT) in post-menopausal women results in increased breast density. This is associated with increased risk of breast cancer and reduced sensitivity of mammography. The purpose of the present study was to compare breast densities of women following surgical menopause with and without use of HRT to women who had natural menopause without use of HRT.Methods: Our institutional Database was queried for post-menopausal women newly diagnosed with breast cancer from 01/2010 to 01/2016. Patients were divided into following groups: 1) natural menopause with no HRT use, 2) history of a bilateral salpingo-oophorectomy (BSO) with no HRT use, 3) history of a BSO with HRT use prior to diagnosis, or 4) history of BSO and use of HRT at the time of diagnosis. BSO may have occurred with or without concurrent hysterectomy.Results: 1106 women were eligible for analysis. 976 (88%) had natural menopause with no HRT, 63 (6%) had a BSO with no HRT, 51 (5%) had a BSO with previous history of HRT, and 16 (1%) had a BSO and were using HRT at time of malignancy diagnosis. Though not statistically significant, women who had a prior BSO and were on HRT at the time of diagnosis had more dense breasts (69% heterogeneously or extremely dense) than women who had natural menopause with no HRT (44% heterogeneously or extremely dense). However, women who had a prior BSO and were on HRT in the past had significantly less dense breasts (p...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research

Related Links:

Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
This study included 74,781 middle-aged Korean women with mammographically determined dense breasts at baseline. Changes in dense breasts were identified by more screening mammograms during follow-up. Hepatic steatosis (HS) was measured using ultrasonography. Flexible parametric proportional hazards models were used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs), and a Weibull accelerated failure time model (AFT) was used to determine the time ratios (TRs) and 95% CIs.ResultsDuring a median follow-up of 4.1  years, 4022 women experienced resolution of the dense breasts. The associatio...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conclusions: radiomic features extracted from tumor edema contribute significantly to predicting tumor histology, increasing the accuracy obtained from the combination of patient clinical characteristics and breast imaging data.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: Combination of AxUS and ultrasound-guided wire localisation of pre-treatment positive CN has high diagnostic accuracy for nodal restaging after NACT in node positive breast cancer patients.ADVANCES IN KNOWLEDGE: Addition of axUS assessment to wire localisation of CN reduces its FNR for detecting residual metastasis after NACT.PMID:34491822 | DOI:10.1259/bjr.20210788
Source: The British Journal of Radiology - Category: Radiology Authors: Source Type: research
CONCLUSIONS: The low 25(OH)D levels were significantly associated with poorer prognosis in Japanese women with operable breast cancer patients treated with NAC.PMID:34487328 | DOI:10.1007/s12282-021-01292-3
Source: Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Biomark Med. 2021 Sep 6. doi: 10.2217/bmm-2020-0717. Online ahead of print.ABSTRACTBackground: Inflammatory breast cancer (IBC) is uncommon, aggressive and associated with poor survival outcomes. The lack of prognostic biomarkers and therapeutic targets specific to IBC is an added challenge for clinical practice and research. Inflammatory biomarkers such as neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios (NLR and PLR) demonstrated independent prognostic impact for survival in breast cancer. In our study, these biomarkers were investigated in a cohort of patients with nonmetastatic IBC. Methods: A retrospective c...
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Authors: Source Type: research
ConclusionPatients with ER-low/HER2 − breast cancer had similar clinicopathological characteristics, treatments, and outcomes as patients with TNBC irrespective of disease setting. Further research is needed to understand predictive and prognostic factors associated with ER-low/HER2− disease.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSION: In conclusion, we found that adherence to the MIND diet was not associated with odds of BC in this case-control study. Further studies are required to confirm these findings.PMID:34482608 | DOI:10.1111/ijcp.14780
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionBeside advance disease status, high Ki-67 proliferation index and lack of systemic chemotherapy are another two important prognostic factors in patients with triple negative breast cancer. Chemotherapy is strongly advised in patients with TNBC whenever they are medically fit.
Source: Surgical Practice - Category: Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSION: In postmenopausal women with newly diagnosed BC, the presence of MetS was associated with smaller tumor size, PR-positive and HER-2-negative status, and the luminal B tumor subtype.PMID:34465534 | DOI:10.1016/j.clbc.2021.07.009
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Hormone Replacement Therapy | Hormones | Hysterectomy | Mammography | Men | Menopause | Statistics | Study | Women